Project Grant R21AI178523
- This $175,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to explore the mechanisms and cell types driving Alternaria alternata (Alt) sensitization and its association with increased asthma risk. The La Jolla Institute for Immunology, a non-profit research institute, will investigate the protective role of Alt-specific T helper 1 interferon response (ThIFNR)...
- Federal Grant Award Summary Award Details: Massachusetts General Hospital (The General Hospital Corporation) received a $250,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion anticipated July 31, 2026. Research Objectives and Deliverables: This grant supports biomedical research investigating lung-resident memory T helper type 2 (TH2) cells as novel...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The key objectives are to: 1) characterize a targetable stromal factor that alters immune cell accumulation in the lung, and 2) define the downstream effects of these immune cells on...
- The National Institute of Allergy and Infectious Diseases (NIAID), as part of the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $300,000 Project Grant to Cellergy Pharma Inc. The grant, effective February 1, 2025 through January 31, 2027, supports the development of a bispecific antibody drug targeting IgE-producing B cells to treat severe allergic diseases. The key products and services to be delivered under this Phase I grant include: Determining the...
- Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $670,017 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 4, 2026 through January 31, 2031. This research project investigates a novel regulatory pathway in innate type 2 lymphocytes (ILC2s) that controls cytokine sensing and immune response in allergic...
- Federal Project Grant Award Summary Indiana University Indianapolis received a $162,000 Project Grant award dated June 18, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research project, concluding May 31, 2027, investigates the critical and opposing roles of transforming growth factor beta (TGFB) signaling in T follicular helper (TFH) cells and mast cells (MC) in allergic disease...
- Federal Grant Award Summary National Jewish Health received a $776,394 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 19, 2026, with completion targeted for January 31, 2031. The award funds biomedical research investigating prenatal programming of immune cells, specifically examining how maternal exposure to diesel exhaust particles (DEP) triggers airway remodeling...
- This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $332,212 to The Regents of the University of California, San Francisco on May 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project titled "RNA Regulatory Circuits in Allergic Airway Inflammation." The project, scheduled for completion by December 31, 2026, funds research to identify post-transcriptional RNA regulatory mechanisms that drive...
- Federal Project Grant Award Summary The University of Illinois received a $760,759 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on May 15, 2025, with completion targeted for February 28, 2029. The research will be conducted at the University of Illinois in Chicago, IL. This project grant funds basic science research investigating the immunoregulatory mechanisms of conventional dendritic cell...
REGULATION OF IGE PRODUCTION DURING AEROALLERGEN SENSITIZATION - PROJECT SUMMARY/ABSTRACT ASTHMA IS A DEBILITATING LUNG DISEASE MARKED BY REVERSIBLE AIRWAY OBSTRUCTION THAT AFFECTS OVER 5% OF THE US POPULATION AND IS GROWING IN PREVALENCE. IN THE MAJORITY OF CASES OF ASTHMA, ALLERGIC INFLAMMATION AROUND THE BRONCHIAL AIRWAYS CONTRIBUTES TO DISEASE PATHOGENESIS. A KEY PATHWAY IN THE INITIATION OF ALLERGIC IMMUNE RESPONSES IS ELICITED BY ANTIBODIES OF THE IGE ISOTYPE. IN ALLERGIC INDIVIDUALS, IGE ANTIBODIES ARE PRODUCED WITH SPECIFICITY FOR COMPONENTS OF HARMLESS ENVIRONMENTAL SUBSTANCES, TERMED ALLERGENS. HOWEVER, THE MECHANISMS RESPONSIBLE FOR THE PRODUCTION OF IGE SPECIFIC FOR ALLERGENS INHALED INTO THE RESPIRATORY TRACT (AEROALLERGENS) REMAIN POORLY CHARACTERIZED. ONE OF THE MAJOR LIMITATIONS IN UNDERSTANDING THE PROCESS OF ALLERGIC SENSITIZATION THROUGH THE RESPIRATORY TRACT HAS BEEN TECHNICAL DIFFICULTY IN DIRECT STUDIES OF IGE PRODUCING PLASMA CELLS AND THEIR B CELL PRECURSORS. MY LABORATORY HAS DEVELOPED METHODOLOGY ENABLING THE SENSITIVE IDENTIFICATION OF THESE RARE IGE- EXPRESSING CELLS BY FLOW CYTOMETRY AND MICROSCOPY. THE FOCUS OF THIS PROJECT IS TO APPLY THIS ROBUST METHODOLOGY TO STUDY THE GENERATION OF IGE-EXPRESSING CELLS FOLLOWING AEROALLERGEN EXPOSURE THROUGH THE RESPIRATORY TRACT. IN ORDER TO DO A DETAILED ANALYSIS OF TISSUES INVOLVED IN RESPIRATORY TRACT IMMUNITY, WE WILL STUDY MOUSE MODELS OF ALLERGIC AIRWAY DISEASE. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO STUDY THE CELLULAR RESPONSE LEADING TO THE PRODUCTION OF IGE IN ALLERGIC SENSITIZATION THROUGH THE RESPIRATORY TRACT. THE SPECIFIC AIMS OF THIS STUDY ARE TO: 1) CHARACTERIZE THE GENERATION AND FATE OF IGE B CELLS AND PLASMA CELLS AND THEIR TISSUE LOCALIZATION IN DIFFERENT MODELS OF AEROALLERGEN SENSITIZATION AND 2) DETERMINE THE RELATIVE ABUNDANCE OF ALLERGEN-SPECIFIC IGE B CELLS AND PLASMA CELLS COMPARED WITH OTHER ISOTYPES (IGM, IGG, AND IGA) AND ESTABLISH THEIR CLONAL RELATIONSHIPS. THE RESULTS FROM THESE STUDIES WILL PROVIDE IMPORTANT INSIGHTS INTO IGE PRODUCTION AFTER ALLERGEN EXPOSURE VIA THE RESPIRATORY TRACT. MORE BROADLY, THIS STUDY WILL INCREASE OUR UNDERSTANDING OF THE WAYS IN WHICH WE MAY DEVELOP SENSITIZATION VERSUS TOLERANCE TO AEROALLERGENS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $205.0k | 4/18/25 | ||
| Not listed | $24.5k | 9/11/24 | ||
| Not listed | $24.5k | 9/11/24 | ||
| Not listed | $220.8k | 5/24/24 | ||
| Not listed | $220.8k | 5/24/24 |